ClinicalTrials.gg
RecruitingNCT06067438Updated May 22, 2026

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

A Phase 2 interventional study of Amiodarone Hydrochloride and Saline in Atrial Fibrillation and Esophageal Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.

Planned enrollment
30th of 46
90 · median 124
Started
2024
with 5 others
Phase 2
2 of 46
1 open now
Primary completion
2027-08
later than 5 of 11 live
Registered
38th of 46
by date

Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 30th largest by planned enrollment, is one of 6 that started in 2024, is one of 2 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 38th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About amiodarone

Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing amiodarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients to receive preventative amiodarone or not. Further, there is no standard recommendation or guideline for preventative medications, such as amiodarone, to decrease the risk of AF in patients having MIE performed for cancer. In fact, most medical centers in the United States and around the world do not give preventative amiodarone after esophagectomy. Giving amiodarone after MIE surgery may be able to reduce the risk of AF for patients with esophageal cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the effect of prophylactic amiodarone on the rate of atrial fibrillation (AF) in patients undergoing minimally invasive esophagectomy (MIE).

SECONDARY OBJECTIVES:

I. In each subobjective, below, evaluations of the effects of prophylactic amiodarone on the following will be made:

  • Ia. Postoperative (PostOp) rapid ventricular response;
  • Ib. Postop pulmonary complications;
  • Ic. Postop anastomotic leak;
  • Id. Intensive care unit (ICU) readmission;
  • Ie. ICU length of stay (LOS);
  • If. Hospital LOS;
  • Ig. 30-day readmission;
  • Ih. Inpatient mortality;
  • Ii. 30-day mortality;
  • Ij. Adverse events;
  • Ik. Time to AF;

Il. Evaluating the association between therapeutic (or serum levels and the development of AF in the experimental group only.

EXPLORATORY OBJECTIVE:

I. To evaluate the effect of prophylactic amiodarone administration on hospital cost of care.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive amiodarone hydrochloride intravenously (IV) for 4 days and then via a feeding tube for 3 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo (normal saline) IV for 4 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for 60 days following discharge from hospitalization after MIE.

03

Conditions studied

  • Atrial Fibrillation
  • Esophageal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients undergoing MIE will be evaluated for potential enrollment

    • Indication of cancer, esophageal dysplasia or esophageal dysmotilities
  • Age > 18 years
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • History of chronic or paroxysmal AF, or atrial flutter
  • Previous severe adverse reaction or to amiodarone (e.g., pulmonary toxicity/fibrosis, hepatotoxicity, thyroid dysfunction)
  • Current preoperative use of amiodarone, as baseline home medication
  • Development of AF intraoperatively
  • Pregnancy

    • Negative pregnancy tests are required for participants of (PCBP) on Day of Surgery (DOS)
  • Breastfeeding/chest feeding
  • Aborted MIE operation
  • (Fridericia formula) > 500 for heart rate (HR) 60-100 within 30 days

    • For patients with a heart rate (HR) of between 50-59 on their pre-operative screening electrocardiography (), we will first review evidence of chronotropic cardiac response to exercise before inclusion in the study. If a patient's HR increases to ≥ 100 with exercise, the patient is eligible for inclusion of study. Exercise testing options may include a stair climb, a brisk walk, or supine leg-lifts prior to surgery. If exercise is not an option, we can review results of formal stress testing chronotropic response (ie. HR ≥ 100). HR monitoring can be collected by either pulse oximeter or EKG
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Arm I (amiodarone hydrochloride)

    Patients receive amiodarone hydrochloride IV for 4 days and then via a feeding tube for 3 days on study.

    Drug: Amiodarone Hydrochloride

  • Placebo comparator
    Arm II (normal saline)

    Patients receive normal saline IV for 4 days on study.

    Other: Saline

Interventions

  • DrugAmiodaroneStudies of AmiodaroneAmiodarone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV and via feeding tube

    Also known as: Cordarone, Nexterone

  • OtherSaline

    Given IV

    Also known as: ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%

06

What researchers measure

Primary outcomes

  1. Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone

    Will be a binary variable (yes/no) and analyzed using a one-sided test of two proportions at an alpha level of 0.05.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 7, after last dose of enteral amiodarone

Secondary outcomes

  1. Postoperative (PostOp) rapid ventricular response

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% confidence interval (CI) of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to discharge (DC) from hospital.

  2. Postop pulmonary complications

    Including pneumonia, acute respiratory distress syndrome, acute pulmonary edema, and chylothorax. Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30

  3. Anastomotic leak

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30

  4. ICU Readmission

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30

  5. ICU length of stay (LOS)

    Will be assessed in days. Analysis: Wilcoxon rank sum test

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time patient is moved out of ICU

  6. Hospital LOS

    Will be assessed in days. Analysis: Wilcoxon rank sum test

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time of discharge from hospital

  7. 30 Day readmission rate

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: Day of discharge (DC) from hospital to 30 days after discharge

  8. Inpatient morality

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time of discharge from hospital

  9. Incidence of mortality within 30 days of surgery

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30

  10. Incidence and type of adverse events

    Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30

  11. Time to AF

    Analysis: Log-rank test.

    Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 7

  12. Serum amiodarone level, classified as therapeutic or subtherapeutic

    Time frame: Post-operative day (POD) 2 to post-operative day (POD) 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Oct 4, 2023
StartActual
Jun 21, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067438
Responsible party
Stephanie Wood (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Oct 4, 2023
Start date
Jun 21, 2024
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Stephanie Wood
principal investigator · OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amiodarone

Start the discussion